Nymox Pharmaceutical Corporation (NYMXF)
USD 0.14
(-8.36%)
USD 0.14
(-8.36%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -8.35 Million USD | -25.53% |
| 2022 | -6.65 Million USD | 46.8% |
| 2021 | -12.5 Million USD | -6.69% |
| 2020 | -11.72 Million USD | 12.05% |
| 2019 | -13.32 Million USD | -25.22% |
| 2018 | -10.64 Million USD | 19.6% |
| 2017 | -13.23 Million USD | -2.84% |
| 2016 | -12.87 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q3 | -1.01 Million USD | 7.73% |
| 2023 Q4 | -4.85 Million USD | -378.6% |
| 2023 Q2 | -1.09 Million USD | 20.65% |
| 2023 Q1 | -1.38 Million USD | -182.79% |
| 2022 Q1 | -5.07 Million USD | -81.08% |
| 2022 Q2 | -1.77 Million USD | 65.06% |
| 2022 Q4 | 1.67 Million USD | 213.19% |
| 2022 FY | -6.65 Million USD | 46.8% |
| 2022 Q3 | -1.47 Million USD | 16.64% |
| 2021 Q4 | -2.8 Million USD | 14.94% |
| 2021 FY | -12.5 Million USD | -6.69% |
| 2021 Q3 | -3.29 Million USD | 0.0% |
| 2020 FY | -11.72 Million USD | 12.05% |
| 2019 FY | -13.32 Million USD | -25.22% |
| 2018 FY | -10.64 Million USD | 19.6% |
| 2017 FY | -13.23 Million USD | -2.84% |
| 2016 FY | -12.87 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -525.266% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -65.527% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 53.213% |
| Nascent Biotech, Inc. | -2.22 Million USD | -274.46% |
| Rebus Holdings, Inc. | -664 Thousand USD | -1157.53% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 110.201% |
| Qrons Inc. | -643.67 Thousand USD | -1197.234% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -2043.389% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 84.957% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1909.729% |
| Skye Bioscience, Inc. | -13.67 Million USD | 38.925% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 88.368% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 269.895% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -3090.359% |
| SQZ Biotechnologies Company | -75.82 Million USD | 88.988% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -192.93% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -443.602% |
| Mesoblast Limited | -84.14 Million USD | 90.077% |
| Marizyme, Inc. | -34.08 Million USD | 75.504% |
| Genus plc | 6.4 Million USD | 230.469% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 185.707% |
| Pharming Group N.V. | -4.87 Million USD | -71.123% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -320.342% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -796.519% |
| ContraFect Corporation | -56.88 Million USD | 85.322% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -83.326% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -495.582% |
| IMV Inc. | -38.67 Million USD | 78.408% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -203.544% |
| MultiCell Technologies, Inc. | -722.81 USD | -1155113.68% |
| ONE Bio Corp. | 13.68 Million USD | 161.031% |
| Accustem Sciences Inc. | -3.74 Million USD | -122.88% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 85.845% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -1628.557% |
| Q BioMed Inc. | -3.44 Million USD | -142.337% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 335.876% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -217.79% |
| Biomind Labs Inc. | -1 Million USD | -727.058% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 84.811% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -187.807% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -25.601% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -347.872% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -27777.938% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 47.384% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -332.058% |
| GB Sciences, Inc. | -1.42 Million USD | -487.817% |
| Alpha Cognition Inc. | -9.7 Million USD | 13.967% |
| HST Global, Inc. | -140.9 Thousand USD | -5825.894% |
| CSL Limited | 3.7 Billion USD | 100.226% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -642.284% |
| Halberd Corporation | -75.05 Thousand USD | -11025.916% |
| Enzolytics Inc. | -2.14 Million USD | -288.589% |
| Agentix Corp. | -1.37 Million USD | -508.709% |
| Resverlogix Corp. | -12.74 Million USD | 34.505% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -163.55% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 98.036% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -699.808% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -186.013% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -428.697% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -145.229% |
| AVAX Technologies, Inc. | 6.69 Million USD | 224.759% |
| Zenith Capital Corp. | -8.94 Million USD | 6.631% |
| Genscript Biotech Corporation | -415.79 Million USD | 97.992% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -47830.658% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -240.078% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -4768.534% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -316.509% |
| Kadimastem Ltd | -3.04 Million USD | -174.648% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -748.532% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -564.809% |
| BioStem Technologies, Inc. | -7.77 Million USD | -7.341% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -4500.931% |
| LadRx Corporation | -3.82 Million USD | -118.379% |
| Cell Source, Inc. | -4.32 Million USD | -93.048% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1115.518% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1115.518% |
| NovAccess Global Inc. | -2.46 Million USD | -238.501% |
| Affymax, Inc. | -15.04 Million USD | 44.504% |
| Itoco Inc. | -919.14 Thousand USD | -808.458% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -97.008% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -646.202% |
| Mobile Lads Corp. | -554.55 Thousand USD | -1405.725% |
| CytoDyn Inc. | -18.05 Million USD | 53.76% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -33074.414% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -3694.109% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -1378.601% |
| SYBLEU INC | -149.18 Thousand USD | -5497.265% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -359.721% |
| International Stem Cell Corporation | -663 Thousand USD | -1159.427% |
| Bioxytran, Inc. | -3.82 Million USD | -118.578% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -15762.462% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -40952.114% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 76.976% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -416.069% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -1034.765% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -168.402% |
| Neutra Corp. | -229.48 Thousand USD | -3538.566% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 52.392% |
| PureTech Health plc | -146.19 Million USD | 94.289% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 61.147% |
| IXICO plc | -1.43 Million USD | -481.072% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 12.022% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 93.145% |
| CSL Limited | 3.81 Billion USD | 100.219% |
| Cellectis S.A. | -108.85 Million USD | 92.329% |